HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells

OncoImmunology

Volumn 3, Issue 11, 2014, Pages e956012-1-e956012-17

  Miller, Megan Jo ^a   Foy, Kevin C ^b   Overholser, Jay P ^b   Nahta, Rita ^c   Kaumaya, Pravin T P ^a,b,d  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Antibodies; HER 1; HER 2; HER 3 (erbb3); IGF 1R; immunogenicity; Immunotherapy; peptide vaccines; peptidomimetics; receptor tyrosine kinases

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPITOPE; SOMATOMEDIN C RECEPTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS ASSAY; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOTHERAPY; MOUSE; MTT ASSAY; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RABBIT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; WESTERN BLOTTING;

EID: 84938630138     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.956012     Document Type: Article

References (81)

1. Y.Ueno, H.Sakurai, S.Tsunoda, M.K.Choo, M.Matsuo, K.Koizumi, I.Saiki. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer 2008; 123:340-7; PMID:18398842; http://dx.doi.org/10.1002/ijc.23465
2. S.D.Allen, J.T.Garrett, S.V.Rawale, A.L.Jones, G.Phillips, G.Forni, J.C.Morris, R.G.Oshima, P.T.Kaumaya. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 2007; 179:472-82; PMID:17579068; http://dx.doi.org/10.4049/jimmunol.179.1.472
3. A.K.Koutras, G.Fountzilas, K.T.Kalogeras, I.Starakis, G.Iconomou, H.P.Kalofonos. The upgraded role of HER3 and HER4 receptors in breast cancer. Crit Rev Oncol Hematol 2010; 74:73-8; PMID:19481955; http://dx.doi.org/10.1016/j.critrevonc.2009.04.011
4. Y.Yarden, G.Pines. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012; 12:553-63; PMID:22785351; http://dx.doi.org/10.1038/nrc3309
5. R.Roskoski, Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014; 79:34-74; PMID:24269963; http://dx.doi.org/10.1016/j.phrs.2013.11.002
6. P.Seshacharyulu, M.P.Ponnusamy, D.Haridas, M.Jain, A.K.Ganti, S.K.Batra. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16:15-31; PMID:22239438; http://dx.doi.org/10.1517/14728222.2011.648617
7. M.V.Iorio, P.Casalini, C.Piovan, G.Di Leva, A.Merlo, T.Triulzi, S.Menard, C.M.Croce, E.Tagliabue. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69:2195-200; PMID:19276373; http://dx.doi.org/10.1158/0008-5472.CAN-08-2920
8. H.S.Cho, D.J.Leahy. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002; 297:1330-3; PMID:12154198; http://dx.doi.org/10.1126/science.1074611
9. E.K.Rowinsky. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004; 55:433-57; PMID:14746530; http://dx.doi.org/10.1146/annurev.med.55.091902.104433
10. R.C.Harris, E.Chung, R.J.Coffey. EGF receptor ligands. Exp Cell Res 2003; 284:2-13; PMID:12648462; http://dx.doi.org/10.1016/S0014-4827(02)00105-2
11. S.L.Sierke, K.Cheng, H.H.Kim, J.G.Koland. Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J 1997; 322 (Pt 3):757-63; PMID:9148746; http://www.biochemj.org/bj/322/0757/3220757.pdf
12. P.M.Guy, J.V.Platko, L.C.Cantley, R.A.Cerione, K.L.Carraway, 3rd. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 1994; 91:8132-6; PMID:8058768; http://dx.doi.org/10.1073/pnas.91.17.8132
13. N.Jura, Y.Shan, X.Cao, D.E.Shaw, J.Kuriyan. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A 2009; 106:21608-13; PMID:20007378; http://dx.doi.org/10.1073/pnas.0912101106
14. R.Naidu, M.Yadav, S.Nair, M.K.Kutty. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 1998; 78:1385-90; PMID:9823984; http://dx.doi.org/10.1038/bjc.1998.689
15. H.Friess, Y.Yamanaka, M.S.Kobrin, D.A.Do, M.W.Buchler, M.Korc. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1995; 1:1413-20; PMID:9815939; http://clincancerres.aacrjournals.org/content/1/11/1413.full.pdf
16. C.A.Maurer, H.Friess, B.Kretschmann, A.Zimmermann, A.Stauffer, H.U.Baer, M.Korc, M.W.Buchler. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 1998; 29:771-7; PMID:9712416; http://dx.doi.org/10.1016/S0046-8177(98)90444-0
17. S.T.Lee-Hoeflich, L.Crocker, E.Yao, T.Pham, X.Munroe, K.P.Hoeflich, M.X.Sliwkowski, H.M.Stern. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68:5878-87; PMID:18632642; http://dx.doi.org/10.1158/0008-5472.CAN-08-0380
18. M.Alimandi, A.Romano, M.C.Curia, R.Muraro, P.Fedi, S.A.Aaronson, P.P.Di Fiore, M.H.Kraus. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995; 10:1813-21; PMID:7538656; http://www.ncbi.nlm.nih.gov/pubmed/7538656
19. N.H.Chow, S.H.Chan, T.S.Tzai, C.L.Ho, H.S.Liu. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7:1957-62; PMID:11448910
20. J.Ursini-Siegel, B.Schade, R.D.Cardiff, W.J.Muller. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007; 7:389-97; PMID:17446858; http://dx.doi.org/10.1038/nrc2127
21. N.V.Sergina, M.M.Moasser. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends in molecular medicine 2007; 13:527-34; PMID:17981505; http://dx.doi.org/10.1016/j.molmed.2007.10.002
22. R.Nahta, S.Shabaya, T.Ozbay, D.L.Rowe. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Person Med 2009; 7:263-74; PMID:20300449; http://dx.doi.org/10.2174/187569209790112337
23. T.Vu, F.X.Claret. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol 2012; 2:62; PMID:22720269; http://dx.doi.org/10.3389/fonc.2012.00062
24. J.A.Engelman, K.Zejnullahu, T.Mitsudomi, Y.Song, C.Hyland, J.O.Park, N.Lindeman, C.M.Gale, X.Zhao, J.Christensen, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43; PMID:17463250; http://dx.doi.org/10.1126/science.1141478
25. L.C.Amler. HER3 mRNA as a predictive biomarker in anticancer therapy. Expert Opin Biol Ther 2010; 10:1343-55; PMID:20695834; http://dx.doi.org/10.1517/14712598.2010.512003
26. C.Osipo, K.Meeke, D.Cheng, A.Weichel, A.Bertucci, H.Liu, V.C.Jordan. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. Int J Oncol 2007; 30:509-20; PMID:17203234; http://dx.doi.org/10.3892/ijo.30.2.509
27. T.Frogne, R.V.Benjaminsen, K.Sonne-Hansen, B.S.Sorensen, E.Nexo, A.V.Laenkholm, L.M.Rasmussen, D.J.Riese, 2nd, P.de Cremoux, J.Stenvang, Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009; 114:263-75; PMID:18409071; http://dx.doi.org/10.1007/s10549-008-0011-8
28. T.W.Miller, M.Perez-Torres, A.Narasanna, M.Guix, O.Stal, G.Perez-Tenorio, A.M.Gonzalez-Angulo, B.T.Hennessy, G.B.Mills, J.P.Kennedy, Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 2009; 69:4192-201; PMID:19435893; http://dx.doi.org/10.1158/0008-5472.CAN-09-0042
29. A.W.Hamburger. The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. J Mammary Gland Biol Neoplasia 2008; 13:225-33; PMID:18425425; http://dx.doi.org/10.1007/s10911-008-9077-5
30. B.Schoeberl, E.A.Pace, J.B.Fitzgerald, B.D.Harms, L.Xu, L.Nie, B.Linggi, A.Kalra, V.Paragas, R.Bukhalid, Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2009; 2:ra31; PMID:19567914; http://dx.doi.org/10.1126/scisignal.2000352
31. C.Li, T.M.Brand, M.Iida, S.Huang, E.A.Armstrong, A.van der Kogel, D.L.Wheeler. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discov Med 2013; 16:79-92; PMID:23998444; http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901945/pdf/nihms544643.pdf
32. P.LoRusso, P.A.Janne, M.Oliveira, N.Rizvi, L.Malburg, V.Keedy, L.Yee, C.Copigneaux, T.Hettmann, C.Y.Wu, Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2013; 19:3078-87; PMID:23591447; http://dx.doi.org/10.1158/1078-0432.CCR-12-3051
33. B.Schoeberl, A.C.Faber, D.Li, M.C.Liang, K.Crosby, M.Onsum, O.Burenkova, E.Pace, Z.Walton, L.Nie, An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010; 70:2485-94; PMID:20215504; http://dx.doi.org/10.1158/0008-5472.CAN-09-3145
34. R.K.Jain. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62; PMID:15637262; http://dx.doi.org/10.1126/science.1104819
35. R.Nahta, L.X.Yuan, B.Zhang, R.Kobayashi, F.J.Esteva. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65:11118-28; PMID:16322262; http://dx.doi.org/10.1158/0008-5472.CAN-04-3841
36. X.Huang, L.Gao, S.Wang, J.L.McManaman, A.D.Thor, X.Yang, F.J.Esteva, B.Liu. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 2010; 70:1204-14; PMID:20103628; http://dx.doi.org/10.1158/0008-5472.CAN-09-3321
37. L.Gossage, T.Eisen. Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res 2010; 16:1973-8; PMID:20215532; http://dx.doi.org/10.1158/1078-0432.CCR-09-3182
38. J.T.Garrett, M.G.Olivares, C.Rinehart, N.D.Granja-Ingram, V.Sanchez, A.Chakrabarty, B.Dave, R.S.Cook, W.Pao, E.McKinely, Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 2011; 108:5021-6; PMID:21385943; http://dx.doi.org/10.1073/pnas.1016140108
39. A.V.Kamath, D.Lu, P.Gupta, D.Jin, H.Xiang, A.Wong, C.Leddy, L.Crocker, G.Schaefer, M.X.Sliwkowski, Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 2011; 69(4):1063-9; PMID:22203367; http://dx.doi.org/10.1007/s00280-011-1806-6
40. G.Schaefer, L.Haber, L.M.Crocker, S.Shia, L.Shao, D.Dowbenko, K.Totpal, A.Wong, C.V.Lee, S.Stawicki, A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
41. C.F.McDonagh, A.Huhalov, B.D.Harms, S.Adams, V.Paragas, S.Oyama, B.Zhang, L.Luus, R.Overland, S.Nguyen, Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11-0820
42. A.P.Garner, C.U.Bialucha, E.R.Sprague, J.T.Garrett, Q.Sheng, S.Li, O.Sineshchekova, P.Saxena, C.R.Sutton, D.Chen, An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 2013; 73:6024-35; PMID:23928993; http://dx.doi.org/10.1158/0008-5472.CAN-13-1198
43. C.Mirschberger, C.B.Schiller, M.Schraml, N.Dimoudis, T.Friess, C.A.Gerdes, U.Reiff, V.Lifke, G.Hoelzlwimmer, I.Kolm, RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res 2013; 73:5183-94; PMID:23780344; http://dx.doi.org/10.1158/0008-5472.CAN-13-0099
44. M.D.Lairmore, R.B.Lal, P.T.Kaumaya. Evaluation of immunodominant epitopes of human T-lymphotropic virus type 1 (HTLV-I) using synthetic peptides. Biomed Peptides Proteins Nucleic Acids: Struct, Syn Biol Act 1995; 1:117-22.
45. P.T.Kaumaya, S.Kobs-Conrad, Y.H.Seo, H.Lee, A.M.VanBuskirk, N.Feng, J.F.Sheridan, V.Stevens. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. J Mol Recognit 1993; 6:81-94; PMID:7508238; http://dx.doi.org/10.1002/jmr.300060206
46. Q.Jin, F.J.Esteva. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol 2008; 13:485-98; http://dx.doi.org/10.1007/s10911-008-9107-3
47. D.N.Amin, N.Sergina, L.Lim, A.Goga, M.M.Moasser. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J 2012; 447:417-25; PMID:22853430; http://dx.doi.org/10.1042/BJ20120724
48. Y.Zhang, L.Opresko, H.Shankaran, W.B.Chrisler, H.S.Wiley, H.Resat. HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells. BMC Cell Biol 2009; 10:78; PMID:19878579; http://dx.doi.org/10.1186/1471-2121-10-78
49. C.H.Yeon, M.D.Pegram. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 2005; 23:391-409; PMID:16133791; http://dx.doi.org/10.1007/s10637-005-2899-8
50. D.L.Wheeler, S.Huang, T.J.Kruser, M.M.Nechrebecki, E.A.Armstrong, S.Benavente, V.Gondi, K.T.Hsu, P.M.Harari. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27:3944-56; PMID:18297114; http://dx.doi.org/10.1038/onc.2008.19
51. G.Vlacich, R.J.Coffey. Resistance to EGFR-targeted therapy: a family affair. Cancer Cell 2011; 20:423-5; PMID:22014569; http://dx.doi.org/10.1016/j.ccr.2011.10.006
52. N.V.Sergina, M.Rausch, D.Wang, J.Blair, B.Hann, K.M.Shokat, M.M.Moasser. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445:437-41; PMID:17206155; http://dx.doi.org/10.1038/nature05474
53. N.Jiang, N.F.Saba, Z.G.Chen. Advances in targeting HER3 as an anticancer therapy. Chemother Res Pract 2012; 2012:817304; PMID:23198146; http://dx.doi.org/10.1155/2012/817304
54. R.Nahta, F.J.Esteva. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8:215; PMID:17096862; http://dx.doi.org/10.1186/bcr1612
55. R.Nahta, D.Yu, M.C.Hung, G.N.Hortobagyi, F.J.Esteva. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3:269-80; PMID:16683005; http://dx.doi.org/10.1038/ncponc0509
56. P.M.Saladin, B.D.Zhang, J.M.Reichert. Current trends in the clinical development of peptide therapeutics. IDrugs 2009; 12:779-84; PMID:19943221; http://www.ncbi.nlm.nih.gov/pubmed/19943221
57. J.Reichert. Development trends for peptide therapeutics. Tufts Center for the Study of Drug Development Tufts University, 2008. Peptide Therapeutics Foundation, San Diego CA 92121; http://www.peptidetherapeutics.org/PTF_report_summary_2010.pdf
58. K.C.Foy, Z.Liu, G.Phillips, M.Miller, P.T.Kaumaya. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J Biol Chem 2011; 286:13626-37; PMID:21325276; http://dx.doi.org/10.1074/jbc.M110.216820
59. K.C.Foy, M.J.Miller, N.Moldovan, W.E.Carson Iii, P.T.Kaumaya. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. Oncoimmunology 2012; 1:1048-60; PMID:23170253; http://dx.doi.org/10.4161/onci.20708
60. B.J.Bruno, G.D.Miller, C.S.Lim. Basics and recent advances in peptide and protein drug delivery. Ther Deliv 2013; 4:1443-67; PMID:24228993; http://dx.doi.org/10.4155/tde.13.104
61. M.J.Miller, K.C.Foy, P.T.Kaumaya. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med 2013; 15:166-76; PMID:23545045; http://www.discoverymedicine.com/Megan-Jo-Miller/2013/03/28/cancer-immunotherapy-present-status-future-perspective-and-a-new-paradigm-of-peptide-immunotherapeutics/
62. M.Srinivasan, I.E.Gienapp, S.S.Stuckman, C.J.Rogers, S.D.Jewell, P.T.Kaumaya, C.C.Whitacre. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. J Immunol 2002; 169:2180-8; PMID:12165548; http://dx.doi.org/10.4049/jimmunol.169.4.2180
63. M.Srinivasan, R.M.Wardrop, I.E.Gienapp, S.S.Stuckman, C.C.Whitacre, P.T.Kaumaya. A retro-inverso peptide mimic of CD28 encompassing the MYPPPY motif adopts a polyproline type II helix and inhibits encephalitogenic T cells in vitro. J Immunol 2001; 167:578-85; PMID:11418697; http://dx.doi.org/10.4049/jimmunol.167.1.578
64. S.D.Allen, S.V.Rawale, C.C.Whitacre, P.T.Kaumaya. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. J Pept Res 2005; 65:591-604; PMID:15885118; http://dx.doi.org/10.1111/j.1399-3011.2005.00256.x
65. N.K.Dakappagari, D.B.Douglas, P.L.Triozzi, V.C.Stevens, P.T.Kaumaya. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000; 60:3782-9; PMID:10919651; http://cancerres.aacrjournals.org/content/60/14/3782.full.pdf+html
66. N.K.Dakappagari, J.Pyles, R.Parihar, W.E.Carson, D.C.Young, P.T.Kaumaya. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 2003; 170:4242-53; PMID:12682258; http://dx.doi.org/10.4049/jimmunol.170.8.4242
67. N.K.Dakappagari, R.Sundaram, S.Rawale, A.Liner, D.R.Galloway, P.T.Kaumaya. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T-cell responses in HLA-A*201 mice. J Pept Res 2005; 65:189-99; PMID:15705163; http://dx.doi.org/10.1111/j.1399-3011.2005.00212.x
68. N.K.Dakappagari, K.D.Lute, S.Rawale, J.T.Steele, S.D.Allen, G.Phillips, R.T.Reilly, P.T.Kaumaya. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J Biol Chem 2005; 280:54-63; PMID:15507452; http://dx.doi.org/10.1074/jbc.M411020200
69. P.T.Kaumaya, K.C.Foy, J.Garrett, S.V.Rawale, D.Vicari, J.M.Thurmond, T.Lamb, A.Mani, Y.Kane, C.R.Balint, Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol 2009; 27:5270-7; PMID:19752336; http://dx.doi.org/10.1200/JCO.2009.22.3883
70. Y.Lu, X.Zi, M.Pollak. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004; 108:334-41; PMID:14648698; http://dx.doi.org/10.1002/ijc.11445
71. P.Haluska, J.M.Carboni, C.TenEyck, R.M.Attar, X.Hou, C.Yu, M.Sagar, T.W.Wong, M.M.Gottardis, C.Erlichman. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008; 7:2589-98; PMID:18765823; http://dx.doi.org/10.1158/1535-7163.MCT-08-0493
72. M.K.Robinson, K.M.Hodge, E.Horak, A.L.Sundberg, M.Russeva, C.C.Shaller, M.von Mehren, I.Shchaveleva, H.H.Simmons, J.D.Marks, Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99:1415-25; PMID:18841159; http://dx.doi.org/10.1038/sj.bjc.6604700
73. C.Larbouret, N.Gaborit, T.Chardes, M.Coelho, E.Campigna, C.Bascoul-Mollevi, J.P.Mach, D.Azria, B.Robert, A.Pelegrin. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' downregulation and dimers' disruption. Neoplasia 2012; 14:121-30; PMID:22431920
74. S.Huang, C.Li, E.A.Armstrong, C.R.Peet, J.Saker, L.C.Amler, M.X.Sliwkowski, P.M.Harari. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2013; 73:824-33; PMID:23172311; http://dx.doi.org/10.1158/0008-5472.CAN-12-1611
75. N.Ioannou, A.M.Seddon, A.Dalgleish, D.Mackintosh, H.Modjtahedi. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. BMC Cancer 2013; 13:41; PMID:23367880; http://dx.doi.org/10.1186/1471-2407-13-41
76. J.Dong, A.Sereno, D.Aivazian, E.Langley, B.R.Miller, W.B.Snyder, E.Chan, M.Cantele, R.Morena, I.B.Joseph, A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011; 3:273-88; PMID:21393993; http://dx.doi.org/10.4161/mabs.3.3.15188
77. J.Dong, A.Sereno, W.B.Snyder, B.R.Miller, S.Tamraz, A.Doern, M.Favis, X.Wu, H.Tran, E.Langley, Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 2011; 286:4703-17; PMID:21123183; http://dx.doi.org/10.1074/jbc.M110.184317
78. J.B.Fitzgerald, B.W.Johnson, J.Baum, S.Adams, S.Iadevaia, J.Tang, V.Rimkunas, L.Xu, N.Kohli, R.Rennard, MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther 2014; 13:410-25; PMID:24282274; http://dx.doi.org/10.1158/1535-7163.MCT-13-0255
79. C.Chen, Y.Zhang, J.Li, S.W.Tsao, M.Y.Zhang. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor. Mol Cancer Ther 2014; 13:90-100; PMID:24227890; http://dx.doi.org/10.1158/1535-7163.MCT-13-0558
80. J.T.Garrett, S.Rawale, S.D.Allen, G.Phillips, G.Forni, J.C.Morris, P.T.Kaumaya. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J Immunol 2007; 178:7120-31; PMID:17513761; http://dx.doi.org/10.4049/jimmunol.178.11.7120
81. K.C.Foy, R.M.Wygle, M.J.Miller, J.P.Overholser, T.Bekaii-Saab, P.T.Kaumaya. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol; 191:217-27; PMID:23698748; http://dx.doi.org/10.4049/jimmunol.1300231